Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-11-03 00:00:00 ET · period of report 2022-11-01 · accession 0000899243-22-035035 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-03 | 2022-11-01 | LGND | HIGGINS JOHN L | CEO, Dir | A - Grant | $0.00 | +45.9K | 424.7K | +12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-01 | A | A | 45,922 | $0.00 | 424,731 | D | — | — | (F1) Includes 24,501 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. (F2) Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the OmniAb, Inc. from the Issuer on November 1, 2022. |